SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
251
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in USANA Health Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline – USNA

NEW YORK, March 03, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE: USNA ) and certain of its officers.   The class action, filed in United States District Court, District of Utah, is on behalf of a class consisting of investors who purchased or otherwise acquired USANA securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased USANA securities between March 14, 2014 and February 7, 2017, both dates inclusive, you have until April 14, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. 

On August 16, 2010, USANA announced that it had acquired BabyCare Ltd. (“BabyCare”), a China-based manufacturing company that develops and sells nutritional products primarily for infants.  Over the next six years, USANA steadily expanded BabyCare’s market presence in China.  In February 2013, the Company announced that it had received official government approval from the Ministry of Commerce People’s Republic of China (“MOFCOM”) for direct selling activities in the provinces of Jiangsu and Shaanxi, and the municipality of Tianjin.  In May 2016, USANA announced MOFCOM approval for direct selling activities in the provinces of Liaoning, Shandong, Shanxi, Sichuan, and Guangdong, as well as the municipalities of Dalian, Qingdao, and Shenzhen.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) the Company’s BabyCare subsidiary had engaged in improper reimbursement practices in China; (ii) these practices constituted violations of the Foreign Corrupt Practices Act (“FCPA”); (iii) as such, the Company’s China revenues were in part the product of unlawful conduct and unlikely to be sustainable; (iv) the foregoing conduct, when it became known, was likely to subject the Company to significant regulatory scrutiny; and (v) as a result of the foregoing, USANA’s public statements were materially false and misleading at all relevant times.   

On February 7, 2017, post-market, USANA disclosed that “[t]he Company is voluntarily conducting an internal investigation of its China operations, BabyCare Ltd. . . . focus[ing] on the compliance with the Foreign Corrupt Practices Act . . . and certain conduct and policies at BabyCare, including BabyCare’s expense reimbursement policies.”  USANA advised investors that the Company had retained outside counsel to conduct the investigation and had notified both the SEC and the U.S. Department of Justice of the investigation.

On this news, USANA’s share price fell $7.25, or 11.57%, to close at $55.40 on February 8, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WIN Expands Global Family Support to 124 Countries

Updated Category News Views 55

WIN's Ambitious Global Expansion In the ever-twisting labyrinth of corporate benefits, WIN is stepping up its game. We're talking an expansion that balloons past traditional fertility offerings into a global medley of support services covering every conceivable family and health scenario. It ain’t just about making babies anymore. When you're dealing with 124 countries,...

Continue Reading
Protalix Unveils Promising Gout Therapy Data at ACR 2026

Updated Category News Views 31

A Glimmer of Hope for Gout Sufferers Uncontrolled gout patients may soon see a light at the end of the tunnel. Protalix BioTherapeutics (NYSE American: PLX) just rolled out data at the ACR Convergence 2026, underscoring the potential of their drug candidate, PRX-115. This revelation is a big deal for those grappling with gout that just won't quit, constantly pelted by...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 202

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
EICMA 2026: Groundbreaking Moves in Two-Wheel World

Updated Category News Views 71

Revving Up in Milan: A Record-Breaking EICMA If you're into two-wheelers as much as stocks, EICMA 2026 is where all the action is happening. They opened the door with a bang at Fiera Milano Rho, pulling off their biggest showcase yet. Ten halls packed to the brim, up from nine the previous year, creating buzz across the globe. Showcasing 765 exhibitors and 2,142 brands...

Continue Reading
New Leadership at Reactive Tech: Claudio Facchin Steps In

Updated Category News Views 154

Facchin Joins Reactive Technologies: Power Play or Predictable Move? Let me tell you, the energy sector ain’t for the faint-hearted—especially when you’re talking grid stability. Reactive Technologies just tossed an ace on the table, appointing Claudio Facchin as the new Board Chairman. If you've been around the block, you might recognize Facchin's name from his...

Continue Reading
Leatt Gears Up for Q3 Results Conference Call

Updated Category News Views 106

A good heads-up, folks, isn't just about keeping helmets snug—it’s about knowing when to cash in, especially when Leatt Corporation's got their Q3 results ready to drop. November 12 is the big day, so circle that on your calendars. They're rolling out the numbers before the market even gets its coffee, possibly nudging the ticker, OTCQB:LEAT, in a ripple you’ll want...

Continue Reading
Target Hospitality's Growth and Earnings Analysis Q3 2026

Updated Category News Views 64

Strategic Transformation: A Mixed Bag of Results In the raucous world of high-stakes business, folks, Target Hospitality Corp. (NASDAQ: TH) is making quite the noise. For Q3 2026, they trumpeted a juicy $129.1 million in revenue, which is a solid notch up by 30% from a year before. Yet, like a seasoned trader facing a knife-edge call, they're handling a bittersweet...

Continue Reading
Energenesis Tackles Space Anemia with ATP Boost

Updated Category News Views 47

Gearing Up for Space Medicine: Enter Energenesis With the cosmic frontier drawing investor eyes and day-to-day operations inching skyward, here comes Energenesis Biomedical (TWSE: 6657), poking its head into space medicine. This isn’t just another biotech firm looking to throw drugs at terrestrial problems. No, Energenesis shot its shot at TASTI 2026 with its...

Continue Reading
Veterinary Stories Transform Pet Care in New Docuseries

Updated Category News Views 132

Peeling Back the Scrubs: Hidden Heroes in Vet Medicine Everyone's all-hands-on-deck when it's your furball on the line, but how much do you really know about what happens in those vet offices? Finally, National Veterinary Associates (NVA) is unzipping that mystery with a no-bones-about-it docuseries, Advancing Veterinary Medicine: Our Stories, right out of Austin, Texas....

Continue Reading
Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Updated Category News Views 55

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Continue Reading

Top 5 Most Recently Viewed Articles

Qatar Airways Reveals New Lounge and Terminal at JFK Airport

Updated Category News Views 254

Qatar Airways Expands Presence at JFK Airport Qatar Airways is set to enhance its operations at John F. Kennedy International Airport by moving to the New Terminal One, which promises a first-of-its-kind experience for travelers in the United States. This airline, renowned for its exceptional service, is preparing to introduce a dedicated lounge in 2026, significantly...

Continue Reading
Venture Global Faces Class Action Amid Legal Challenges

Updated Category News Views 227

Venture Global Faces Legal Action Venture Global, Inc. has recently been embroiled in a securities class action lawsuit filed in the Southern District of New York. The lawsuit pertains to all individuals or entities who acquired Venture's securities during its initial public offering around January 2025, seeking to recover damages under federal securities laws. Claims of...

Continue Reading
Join Aclaris Therapeutics' R&D Day on Immuno-Inflammatory Gaps

Updated Category News Views 151

Aclaris Therapeutics R&D Day Focused on Patient Needs Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical organization based in Pennsylvania, is set to host its highly anticipated R&D Day. This event is dedicated to exploring the evolving landscape of immuno-inflammatory diseases and the innovative solutions that the company is developing. The R&D Day will take...

Continue Reading
Cloudelligent Achieves Sixth Ranking in Global MSP List

Updated Category News Views 137

Cloudelligent Celebrates Top Ranking in MSP 501 Cloudelligent, a prominent Managed Cloud Services provider, has reached an impressive milestone by being recognized as the sixth-ranked company on Channel Futures' prestigious MSP 501 list for the year. This distinction is not merely a testament to their robust performance; it underscores their relentless commitment to...

Continue Reading
Lithia Motors Sees Earnings Growth, Yet Shares Decline

Updated Category News Views 116

Lithia Motors Reports Strong Financial Performance Why are Lithia Motors, Inc.‘s shares slipping despite a substantial earnings beat and impressive profitability growth? As investors grapple with mixed signals from the company’s latest financial performance, the story behind the numbers holds the key to understanding market reactions. Lithia Motors shares are trading...

Continue Reading